CBG is considered to be the mother of all cannabinoids. This is because CBG-A, the acidic form of CBG, breaks down to form CBG, CBD, THC, and CBC. “Minor cannabinoids are gaining popularity, with CBG, in particular, poised to become the next big thing.”
Source: Botanacor
Inflammatory bowel disease: CBG seems to reduce the inflammation associated with Inflammatory Bowel Disease.
Glaucoma: A study suggests that CBG is effective in treating glaucoma because it reduces intraocular pressure. It is a powerful vasodilator and has neuroprotective effects.
Bladder dysfunctions: Studies show that CBG has the potential to treat bladder dysfunction as it is shown to ease bladder contractions.
Huntington’s disease: CBG might have neuroprotective properties, according to a 2015 study that looked at mice with a neurodegenerative condition called Huntington’s disease. The study concluded that CBG might show promise in treating other neurodegenerative conditions as well.
Bacterial infections: A study suggests that CBG can kill bacteria, particularly Methicillin-resistant Staphylococcus Aureus (MRSA), which causes drug-resistant staph infections. These infections can be hard to treat and fairly dangerous. The cannabinoid was able to penetrate the bacteria’s biofilm, a robust film-layer that the microorganism develops to protect itself.
Cancer: CBG has shown great promise as a cancer fighter. Specifically, CBG was shown to block receptors that cause cancer cell growth. In one such study, it was shown to inhibit the growth of colorectal cancer cells in mice, thereby slowing colon cancer growth. CBG inhibited tumors and chemically-induced colon carcinogenesis, therefore demonstrating a very exciting possibility for a cure for colorectal cancer.
Cachexia: A 2017 study showed that CBG was a very effective appetite stimulant in rats. This may lead to a novel non-psychotropic therapeutic option for Cachexia, the muscle wasting and severe weight loss seen in late-stage cancer and other diseases.
Source: Medically reviewed by Debra Rose Wilson, PHD., MSN, R.N., AHN-BC, CHT.
“CBG or Cannabigerol is a non-intoxicating cannabinoid that is being marketed for the alleviation of anxiety, pain, infection, nausea, and even the treatment of cancer.”
Source: Harvard Health Publishing / Harvard Medical School.
“Experiments in mice have shown that it can decrease inflammation associated with inflammatory bowel disease and that it can slow the growth of colorectal cancer. In cells, it inhibits glioblastoma multiform cells (The type of cancer that Senator John McCain suffered from).”
Source: Harvard Health Publishing / Harvard Medical School.
“CBG has also been shown to act as an antimicrobial against many different agents, including the difficult-to-treat MRSA bug that causes so many hospital infections. Additionally, CBG is an appetite stimulant that may help treat bladder contractions.”
Source: Harvard Health Publishing Harvard Medical School.
“The most common conditions the complete sample reported using CBG to treat were anxiety (51.2%), chronic pain (40.9%), depression (33.1%), and insomnia or disturbed sleep (30.7%). Efficacy was highly rated, with the majority reporting their conditions were “very much improved” or “much improved” by CBG. Furthermore, 73.9% claimed the superiority of CBG-predominant cannabis over conventional medicines for chronic pain, 80% for depression, 73% for insomnia, and 78.3% for anxiety. 44% of CBG-predominant cannabis users reported no adverse events, with 16% noting dry mouth, 15% sleepiness, 11.8% increased appetite, and 8.7% dry eyes. 84.3% reported no withdrawal symptoms, with sleep difficulties representing the most frequently endorsed withdrawal symptom (endorsed by two respondents).
Conclusions: This is the first patient survey of CBG-predominant cannabis use to date and the first to document self-reported efficacy of CBG-predominant products, particularly for anxiety, chronic pain, depression, and insomnia. Most respondents reported greater efficacy of CBG-predominant cannabis over conventional pharmacotherapy, with a benign adverse event profile and negligible withdrawal symptoms. This study establishes that humans are employing CBG and suggests that CBG-predominant cannabis-based medicines should be studied in randomized controlled trials.”
Source: NCI CPTAC Antibody Characterization Program / Atypon
